Overview

Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab

Status:
Active, not recruiting

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Summary

The addition of bevacizumab to first-line chemotherapy has been shown to improve progression free survival for patients with ovarian cancer. The purpose of this study is to explore the potential role of clinical and biologic factors in identifying those patients who benefit most from this combined therapy in terms of progression free and overall survival.

Phase:

Phase 4

Details

Lead Sponsor:

National Cancer Institute, Naples

Collaborator:

Mario Negri Institute for Pharmacological Research

Treatments:

Albumin-Bound Paclitaxel
Bevacizumab
Carboplatin
Paclitaxel